AcelRX Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Its lead product, Zalviso (sufentanil sublingual microtablet system), is designed to address IV patient-controlled analgesia problems. AcelRx has announced positive results from each of the three phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. The company has three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office; and ARX-04, a noninvasive, fast-onset sublingual product for the treatment of moderate to severe acute pain.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
AcelRx Pharmaceuticals Inc. Content
Back to Top